Evidence mapPaperPMID 30931606Full record

ArticleJournal of diabetes science and technology2020

Evaluating Glucose Control With a Novel Composite Continuous Glucose Monitoring Index.

Lalantha Leelarathna, Hood Thabit, Malgorzata E Wilinska, Lia Bally, Julia K Mader, Thomas R Pieber, Carsten Benesch, Sabine Arnolds, Terri Johnson, Lutz Heinemann and 3 more

Registry-linked trialAbstract read
In one paragraph

Article in Journal of diabetes science and technology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05574023 (Impact of Continuous Glucose Monitoring), which is not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05574023 nacompletednot on this mapstarted 2021, after this paper: background citation

Impact of Continuous Glucose Monitoring (CGM) With Predictive Alarm for Hypoglycemia (Guardian Connect System) on Glycemic Control and Hypoglycemia Management in a Group of Adolescents With Type 1 Diabetes Mellitus Treated With Multiple Daily Insulin Injections (MDI).

TypeinterventionalSponsorAzienda Ospedaliera Universitaria Integrata VeronaRan2021 to 2022Enrolled20ConditionsType 1 DiabetesArmsUse of Predictive Alarm for hypoglycaemia or hyperglycaemia, Use of Alarm on Threshold for hypoglycaemia or hyperglycaemia
3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Diabetes Technology Meeting 2020.Journal of diabetes science and technology · 2021
    Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Lalantha LeelarathnaManchester Diabetes Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.ORCID 0000-0001-9602-1962
Hood ThabitManchester Diabetes Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
Malgorzata E WilinskaWellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Lia BallyWellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Julia K MaderDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Thomas R PieberDivision of Endocrinology and Diabetology, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
Carsten BeneschProfil Institut für Stoffwechselforschung GmbH, Neuss, Germany.ORCID 0000-0001-6377-2751
Sabine ArnoldsProfil Institut für Stoffwechselforschung GmbH, Neuss, Germany.
Terri JohnsonDexcom Inc, San Diego, CA, USA.
Lutz HeinemannProfil Institut für Stoffwechselforschung GmbH, Neuss, Germany.
Norbert HermannsResearch Institute Diabetes of the Diabetes Academy Mergentheim (FIDAM), Mergentheim, Germany.
Mark L EvansWellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
Roman HovorkaWellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe objective was to describe a novel composite continuous glucose monitoring index (COGI) and to evaluate its utility, in adults with type 1 diabetes, during hybrid closed-loop (HCL) therapy and multiple daily injections (MDI) therapy combined with real-time continuous glucose monitoring (CGM).

methodsCOGI consists of three key components of glucose control as assessed by CGM: Time in range (TIR), time below range (TBR), and glucose variability (GV) (weighted by 50%, 35% and 15%). COGI ranges from 0 to 100, where 1% increase of time <3.9 mmol/L (<70 mg/dl) is equivalent to 4.7% reduction of TIR between 3.9-10 mmol/L (70-180 mg/dl), and 0.5 mmol/L (9 mg/dl) increase in standard deviation is equivalent to 3% reduction in TIR.

resultsContinuous subcutaneous insulin infusion (CSII) users with HbA1c >7.5-10%, had significantly higher COGI during 12 weeks of HCL compared to sensor-augmented pump therapy, mean (SD), 60.3 (8.6) versus 69.5 (6.9),

conclusionsCOGI summarizes three key aspects of CGM data into a concise metric that could be utilized to evaluate the quality of glucose control and to demonstrate the incremental benefit of a wide range of treatment modalities.

Indexed as

Glycemic ControlHealth Status IndicatorsAdultBlood GlucoseBlood Glucose Self-MonitoringDiabetes Mellitus, Type 1Drug Administration ScheduleFemaleGlycated HemoglobinHumansInjections, SubcutaneousInsulinInsulin Infusion SystemsMaleMonitoring, PhysiologicPrognosisBlood GlucoseGlycated HemoglobinInsulinclosed-loop insulin deliverycontinuous glucose monitoringtype 1 diabetes

Identifiers

PMID30931606
PMCPMC7196869

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.